
Evolus, Inc.NASDAQ - EOLS
Reports
Search reports
Name | Reporting Date | Filing Date |
---|
2024-09-30 10-Q | 2024-09-30 | 2024-11-06 |
2024-06-30 10-Q | 2024-06-30 | 2024-07-31 |
2024-03-31 10-Q | 2024-03-31 | 2024-05-07 |
2023-12-31 10-K | 2023-12-31 | 2024-03-07 |
2023-09-30 10-Q | 2023-09-30 | 2023-11-07 |
2023-06-30 10-Q | 2023-06-30 | 2023-08-02 |
2023-03-31 10-Q | 2023-03-31 | 2023-05-09 |
2022-12-31 10-K | 2022-12-31 | 2023-03-08 |
2022-09-30 10-Q | 2022-09-30 | 2022-11-08 |
2022-06-30 10-Q | 2022-06-30 | 2022-08-02 |
2022-03-31 10-Q | 2022-03-31 | 2022-05-10 |
2021-12-31 10-K | 2021-12-31 | 2022-03-03 |
2021-09-30 10-Q | 2021-09-30 | 2021-11-02 |
2021-06-30 10-Q | 2021-06-30 | 2021-08-04 |
2021-03-31 10-Q | 2021-03-31 | 2021-05-12 |
2020-12-31 10-K | 2020-12-31 | 2021-03-25 |
2020-09-30 10-Q | 2020-09-30 | 2020-10-29 |
2020-06-30 10-Q | 2020-06-30 | 2020-08-10 |
2020-03-31 10-Q | 2020-03-31 | 2020-05-11 |
2019-12-31 10-K | 2019-12-31 | 2020-02-25 |
1
2
20 / page
About
Name
Evolus, Inc.
Overview
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Show More
CEO
Mr. David Moatazedi
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Listing Date
2018-02-08
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, 92660, United States
Tel
949-284-4555
Website